Commercial biogas upgrading facilities are expensive and consume energy. Biological biogas upgrading may serve as a low-cost approach because it can be easily integrated with existing facilities at biogas plants. The microbial communities found in anaerobic digesters typically contain hydrogenotrophic methanogens, which can use hydrogen (H 2 ) as a reducing agent for conversion of carbon dioxide (CO 2 ) into methane (CH 4 ). Thus, biological biogas upgrading through the exogenous addition of H 2 into biogas digesters for the conversion of CO 2 into CH 4 can increase CH 4 yield and lower CO 2 emission. The addition of 4 mol of H 2 per mol of CO 2 was optimal for batch biogas reactors and increased the CH 4 content of the biogas from 67 to 94%. The CO 2 content of the biogas was reduced from 33 to 3% and the average residual H 2 content was 3%. At molar H 2 :CO 2 ratios > 4:1, all CO 2 was converted into CH 4 , but the pH increased above 8 due to depletion of CO 2 , which negatively influenced the process stability. Additionally, high residual H 2 content in these reactors was unfavourable, causing volatile fatty acid accumulation and reduced CH 4 yields. The reactor microbial communities shifted in composition over time, which corresponded to changes in the reactor variables. Numerous taxa responded to the H 2 inputs, and in particular the hydrogenotrophic methanogen Methanobacterium increased in abundance with addition of H 2 . In addition, the apparent rapid response of hydrogenotrophic methanogens to intermittent H 2 feeding indicates the suitability of biological methanation for variable H 2 inputs, aligning well with fluctuations in renewable electricity production that may be used to produce H 2 . Our research demonstrates that the H 2 :CO 2 ratio has a significant effect on reactor performance during in situ biological methanation. Consequently, the H 2 :CO 2 molar ratio should be kept at 4:1 to avoid process instability. A shift toward hydrogenotrophic methanogenesis was indicated by an increase in the abundance of the obligate hydrogenotrophic methanogen Methanobacterium .
No takes yet. Share an insight, caveat, or question.
Wahid et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: